SPOP突变与新发转移性去势敏感性前列腺癌结局的关联
这项多中心回顾性研究纳入121例仅接受标准雄激素剥夺治疗的新发转移性去势敏感性前列腺癌患者,其中25例(21%)携带SPOP突变。校正协变量后,SPOP突变与更长的中位无进展生存期(35 vs 13个月;校正HR 0.47;p=0.016)和总生存期(97 vs 69个月;校正HR 0.32;p=0.027)显著相关。
要点
- SPOP突变在新发转移性去势敏感性前列腺癌中占21%。
- SPOP突变者中位无进展生存期35个月,野生型13个月。
- SPOP突变者中位总生存期97个月,野生型69个月。
核心结论
- 在接受标准雄激素剥夺治疗的新发转移性去势敏感性前列腺癌患者中,SPOP突变与更好的无进展生存期和总生存期显著相关。
- 该发现需外部验证后可能辅助临床咨询、预后判断及未来试验设计。
研究设计与样本
- 多中心回顾性研究,收集四家机构新诊断的新发转移性去势敏感性前列腺癌患者数据。
- 纳入标准为接受标准雄激素剥夺治疗而未强化治疗,且通过肿瘤活检靶向二代测序确定SPOP突变状态。
- 共纳入121例男性,其中SPOP突变25例(21%),野生型96例(79%)。
主要发现
- 校正协变量后,SPOP突变与更长的中位无进展生存期显著相关(35 vs 13个月;校正HR 0.47;p=0.016)。
- 校正协变量后,SPOP突变与更长的中位总生存期显著相关(97 vs 69个月;校正HR 0.32;p=0.027)。
- 单变量分析中风险比和p值与校正分析相似。
临床怎么用
- SPOP突变状态可能有助于新发转移性去势敏感性前列腺癌患者的预后咨询。
- 该结果需外部验证后方可用于临床决策或未来临床试验设计。
局限性
- 回顾性研究设计。
- 结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recently, mutations in speckle-type pox virus and zinc finger protein (SPOP) gene (mutant SPOP [mtSPOP]) have been associated with improved outcomes to abiraterone in the castration-resistant setting. We hypothesized that mtSPOP would be associated with improved outcomes to systemic therapy in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC). Retrospective data of newly diagnosed d-mCSPC patients were collected from four institutions. Eligibility criteria included standard androgen deprivation therapy without intensification, and SPOP mutational status (mtSPOP or wild-type SPOP [wtSPOP]) determination by targeted next-generation sequencing from tumor biopsies. A total of 121 men (25 mtSPOP [21%] and 96 wtSPOP [79%]) were included. After adjusting for covariates, mtSPOP was significantly associated with better median progression-free survival (35 vs 13 mo; adjusted hazard ratio [HR] 0.47; p = 0.016) and overall survival (97 vs 69 mo; adjusted HR 0.32; p = 0.027), with similar HR and p value on the univariate analysis. These findings, upon external validation, may assist with counseling and prognostication in the clinic, and inform the design of future clinical trials in this setting. PATIENT SUMMARY: : Presence of tumor mutation in speckle-type pox virus and zinc finger protein (SPOP) gene was associated with improved survival outcomes in men with de novo metastatic castration-sensitive prostate cancer receiving standard androgen deprivation therapy.
引用
- Swami U, Isaacsson Velho P, Nussenzveig R, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol. 2020. PMID: 32624276. doi:10.1016/j.eururo.2020.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。